Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 13/20 | 0.71 |
| ▸ | EGLN2 | Q96KS0 | 16/20 | 0.58 |
| ▸ | THRA | P10827 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8146957 | 0.98 | EGLN1 (0.69) | EGLN1EGLN2THRATHRB | |
| SCHEMBL8141355 | 0.96 | EGLN1 (0.71) | EGLN1EGLN2THRATHRB | |
| SCHEMBL4081668 | 0.91 | EGLN1 (0.59) | EGLN1EGLN2THRATHRB | |
| SCHEMBL4070326 | 0.90 | EGLN1 (0.58) | EGLN1EGLN2 | |
| SCHEMBL3780789 | 0.89 | EGLN1 (0.79) | EGLN1EGLN2THRATHRB | |
| SCHEMBL4075781 | 0.87 | EGLN1 (0.71) | EGLN1EGLN2THRATHRB | |
| SCHEMBL2181308 | 0.85 | EGLN1 (0.72) | EGLN1EGLN2 | |
| SCHEMBL8146026 | 0.85 | EGLN1 (0.49) | EGLN1EGLN2 | |
| SCHEMBL522745 | 0.83 | THRA (0.70) | EGLN1THRATHRB | |
| SCHEMBL522758 | 0.83 | EGLN1 (0.84) | EGLN1EGLN2THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150080425-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. (US) | 2015-03-19 | — | — | US | claimed |
| EP-1463823-B1 | METHODS OF INCREASING ENDOGENOUS ERYTHROPOIETIN (EPO) | FIBROGEN INC (US) | 2013-03-06 | — | — | EP | claimed |
| CN-102552261-A | Methods of increasing endogenous erythropoietin EPO | FIBROGEN INC | 2012-07-11 | — | — | CN | claimed |
| EP-2357175-A1 | isoquinoline derivatives AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | Fibrogen, Inc. (US) | 2011-08-17 | — | — | EP | claimed |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | FIBROGEN, INC. | 2006-09-28 | — | — | US | claimed |
| US-20060178316-A1 | Methods of increasing endogenous erythropoietin (EPO) | FIBROGEN, INC. (US) | 2006-08-10 | — | — | US | claimed |
| EP-1644336-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2006-04-12 | — | — | EP | claimed |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | FIBROGEN, INC. | 2004-12-16 | — | — | US | claimed |
| WO-2004108681-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | claimed |
| EP-2298301-B2 | MEDICAMENTS FOR TREATING ANEMIA ASSOCIATED WITH KIDNEY DISEASE | FIBROGEN INC (US) | 2022-11-16 | — | — | EP | disclosed |
| US-11229637-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210369702-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. (US) | 2021-12-02 | — | — | US | disclosed |
| US-20210060000-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2021-03-04 | — | — | US | disclosed |
| US-10646482-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-1538160-A1 | Substituted Isoquinolin-3-carboxyamides, their preparation and medical use | FIBROGEN, INC. (US) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004108681-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| EP-1463823-A2 | METHODS OF INCREASING ENDOGENOUS ERYTHROPOIETIN (EPO) | FIBROGEN, INC. (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030153503-A1 | Methods of increasing endogenous erythropoietin (EPO) | FIBROGEN, INC. | 2003-08-14 | — | — | US | disclosed |
| WO-2003053997-A2 | METHODS OF INCREASING ENDOGENOUS ERYTHROPOIETIN (EPO) | FIBROGEN, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
| US-6093730-A | AN ENZYME INHIBITORS OF PROLYL-4-HYDROXYLASE FOR TREATING FIBROTIC DISORDERS AND INHIBITING COLLAGEN BIOSYNTHESIS | HOECHST MARION ROUSSEL DEUTSCHLAND GMBH (DE) | 2000-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11229637-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | EGLN1 7/4885EGLN2 3/4885THRA 3533/4885 |
| US-20150080425-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | EGLN1 5/4885EGLN2 3/4885THRA 1520/4885 |
| US-10646482-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | EGLN1 7/4885EGLN2 3/4885THRA 3533/4885 |
| US-20210369702-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | EGLN1 5/4885EGLN2 3/4885THRA 1520/4885 |
| US-20030153503-A1 | Methods of increasing endogenous erythropoietin (EPO) | EPOR, EGLN3, EGLN2 | EGLN1 13/4885EGLN2 3/4885THRA 2906/4885 |
| US-20210060000-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN2, HIF1A | EGLN1 7/4885EGLN2 2/4885THRA 3630/4885 |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | EPOR, HIF1AN, HIF1A | EGLN1 16/4885EGLN2 4/4885THRA 1089/4885 |
| US-20060178316-A1 | Methods of increasing endogenous erythropoietin (EPO) | EPOR, EGLN3, EGLN2 | EGLN1 13/4885EGLN2 3/4885THRA 2906/4885 |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | EPOR, HIF1AN, HIF1A | EGLN1 12/4885EGLN2 5/4885THRA 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.